TriSalus Life Sciences (TLSI) Projected to Post Quarterly Earnings on Monday

TriSalus Life Sciences (NASDAQ:TLSI - Get Free Report) is anticipated to post its quarterly earnings results before the market opens on Monday, April 7th. Analysts expect TriSalus Life Sciences to post earnings of ($0.35) per share for the quarter. TriSalus Life Sciences has set its FY 2025 guidance at EPS.

TriSalus Life Sciences (NASDAQ:TLSI - Get Free Report) last released its quarterly earnings data on Thursday, March 27th. The company reported ($0.35) EPS for the quarter, meeting the consensus estimate of ($0.35). The business had revenue of $8.26 million for the quarter, compared to the consensus estimate of $8.12 million. On average, analysts expect TriSalus Life Sciences to post $-2 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

TriSalus Life Sciences Price Performance

Shares of TriSalus Life Sciences stock traded down $0.31 during trading hours on Thursday, reaching $5.22. The company's stock had a trading volume of 27,986 shares, compared to its average volume of 43,138. The firm has a 50 day moving average price of $5.44 and a 200-day moving average price of $4.75. The stock has a market cap of $159.17 million, a P/E ratio of -2.10 and a beta of 0.48. TriSalus Life Sciences has a one year low of $3.50 and a one year high of $10.42.

Analyst Upgrades and Downgrades

Several equities research analysts have recently issued reports on TLSI shares. Lake Street Capital began coverage on TriSalus Life Sciences in a research note on Thursday, February 13th. They issued a "buy" rating and a $10.00 price objective for the company. Cantor Fitzgerald began coverage on TriSalus Life Sciences in a research report on Tuesday, December 17th. They issued an "overweight" rating and a $10.00 price target for the company. Canaccord Genuity Group reaffirmed a "buy" rating and set a $11.00 price objective on shares of TriSalus Life Sciences in a research note on Friday, March 28th. Finally, Roth Mkm reissued a "buy" rating and issued a $11.00 target price on shares of TriSalus Life Sciences in a research note on Friday, January 24th. Eight analysts have rated the stock with a buy rating and two have given a strong buy rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of "Buy" and a consensus target price of $11.56.

Insider Activity

In other TriSalus Life Sciences news, insider Sean Murphy purchased 15,000 shares of the stock in a transaction dated Monday, January 27th. The stock was purchased at an average price of $5.31 per share, with a total value of $79,650.00. Following the transaction, the insider now owns 182,732 shares of the company's stock, valued at approximately $970,306.92. This trade represents a 8.94 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Mary T. Szela acquired 4,826 shares of the business's stock in a transaction that occurred on Monday, January 27th. The shares were acquired at an average cost of $5.42 per share, for a total transaction of $26,156.92. Following the completion of the acquisition, the chief executive officer now owns 429,503 shares of the company's stock, valued at $2,327,906.26. This trade represents a 1.14 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Over the last ninety days, insiders purchased 54,856 shares of company stock valued at $294,608. 32.80% of the stock is currently owned by company insiders.

About TriSalus Life Sciences

TriSalus Life Sciences, Inc, a medical technology company, researches, develops, and sells drug delivery technologies and immune-oncology therapeutics for the treatment of liver and pancreatic cancer. The company offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial, for locally advanced pancreatic cancer.